ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

In Brief: David Johnson New ACCC President, William Dugan Named President Elect; Straus Resigns From NYMC

March 12, 1982

Fallout Over PSA Guidance Continues—Specialty Groups Dissent, Congress Attacks

July 20, 2012

American Cancer Society Elects Officers, Distributes Awards

November 24, 1995

Collins Sworn In As NIH Director

September 4, 2009

Clinical Trials Approved By NCI CTEP Last Month

January 28, 2011

Construction, Senior Biomedical Service Not In Legislation

November 4, 1988